5/13/2020 | IG | Fitch ups, withdraws Allergan
|
5/13/2020 | IGLM | AbbVie gets tenders for $13.99 billion, €3.06 billion Allergan notes
|
5/5/2020 | IGLM | AbbVie extends exchange for Allergan notes for expected last time
|
4/27/2020 | IGLM | AbbVie extends exchange offers for Allergan notes by one more week
|
4/20/2020 | IGLM | AbbVie extends exchange offers for Allergan notes by one more week
|
4/6/2020 | IGLM | AbbVie extends exchange offers for Allergan notes by two more weeks
|
3/23/2020 | IGLM | Abbvie extends exchange offers for Allergan notes by two more weeks
|
2/24/2020 | IGLM | AbbVie extends exchange offers for Allergan notes by two more weeks
|
1/27/2020 | IGLM | AbbVie extends exchange offers for Allergan notes by one more month
|
12/20/2019 | IGLM | AbbVie extends exchange offers for Allergan notes by one more month
|
11/18/2019 | IGLM | AbbVie extends exchange offers for Allergan notes to Dec. 31
|
11/7/2019 | IGLM | AbbVie announces early participation results of exchange offer for 18 series of Allergan notes
|
10/25/2019 | IGLM | AbbVie launches exchange offer for 18 series of Allergan notes
|
6/25/2019 | BKIG | Moody’s might up Allergan plc
|
11/8/2018 | CVIG | Moody's rates Allergan notes Baa3
|
11/24/2015 | CVIG | Fitch puts Allergan on positive watch
|
11/23/2015 | CVIG | Moody’s reviews Allergan, Actavis, Forest
|
9/11/2015 | SP | New Issue: JPMorgan prices $1 million contingent buffered notes tied to 11 stocks
|
9/10/2015 | SP | New Issue: Deutsche Bank prices $180,623 call warrants linked to 11 stocks
|
9/10/2015 | SP | New Issue: Deutsche Bank prices $5.96 million knock-out notes on stock basket
|
9/8/2015 | SP | New Issue: Deutsche Bank prices $1.29 million knock-out notes on stock basket
|
9/1/2015 | SP | New Issue: JPMorgan prices $650,000 autocallable contingent interest notes linked to Allergan
|
8/26/2015 | SP | JPMorgan plans contingent interest autocallables linked to Allergan
|
5/12/2015 | BKCVIG | S&P lowers Allergan
|
4/22/2015 | IG | Moody’s drops Allergan to Baa3
|
3/17/2015 | BKCVIG | Fitch cuts Allergan, affirms Actavis
|
3/3/2015 | IG | Market Commentary: Actavis megadeal prices; Exxon upsizes; Exxon trades; AT&T firms; Verizon mixed
|
3/3/2015 | EMHYMUPFPV | Market Commentary: Actavis megadeal prices; Exxon upsizes; Exxon trades; AT&T firms; Verizon mixed
|
3/3/2015 | IG | New Issue: Actavis prices $21 billion 10-part offering of senior notes
|
3/3/2015 | IG | Actavis sets guidance for 10-part bond offering; pricing Tuesday; around $20 billion size eyed
|
3/2/2015 | EMHYMUPFPV | Market Commentary: MetLife, Discover, American Airlines price; Actavis megadeal on deck; Discover, MetLife firm
|
3/2/2015 | IG | Market Commentary: MetLife, Discover, American Airlines price; Actavis jumbo bond on deck; Discover, MetLife firm
|
3/2/2015 | IG | Actavis to price around $20 billion of bonds in nine parts Tuesday to fund Allergan acquisition
|
1/8/2015 | BKBWCAHYLMLW | Valeant cuts leverage to 3.5x, holds out prospect of more debt paydowns
|
11/18/2014 | BK | Actavis gives more details on new debt for Allergan acquisition
|
11/17/2014 | BKBWIG | Actavis plans to issue $27.5 billion of new debt at an average of 4.25% to fund Allergan merger
|
9/25/2014 | IG | Moody’s reviews Allergan
|
4/23/2014 | CVIG | S&P: Allergan on watch
|
4/23/2014 | CVIG | Fitch puts Allergan on watch
|
4/22/2014 | BKHY | Moody's revises Valeant outlook to developing
|
4/22/2014 | IG | Moody's revises Allergan outlook to negative
|
4/21/2014 | BK | Valeant expects up to $15 billion commitments to fund Allergan merger
|
4/11/2014 | SP | New Issue: Bank of America prices $35 million more 8% floored participation notes tied to Allergan
|
2/12/2014 | SP | Month kicks off with volume up 17%, Credit Suisse's $225.9 million deal, year's largest so far
|
2/6/2014 | SP | New Issue: Bank of America prices $35 million 8% floored participation notes tied to Allergan
|
3/11/2013 | IG | Market Commentary: Midday Commentary: Secondary trading better; Allergan spreads continue to tighten
|
3/8/2013 | IG | Market Commentary: Midday Commentary: Secondary sees Allergan notes trading better compared to new issue spreads
|
3/8/2013 | IG | Market Commentary: Scotiabank, Prospect Capital cap busy week of issuance; Avon, Allergan notes trade better
|
3/7/2013 | IG | New Issue: Allergan sells $600 million of notes in five-, 10-year maturities
|
3/7/2013 | IG | Market Commentary: Avon, Progress Energy sell in 'fatigued' primary; new issues trade better during strong session
|
3/7/2013 | CVIG | Fitch rates Allergan notes A+
|
3/7/2013 | CVIG | S&P rates Allergan notes A+
|
3/7/2013 | CVIG | Moody's: Allergan notes A3
|
3/7/2013 | IG | Allergan prepares Thursday note sale in five-, 10-year maturities
|
1/24/2013 | CVIG | Moody's: Allergan unchanged
|
1/23/2013 | CVIG | Fitch: Allergan unchanged
|
8/6/2012 | CVIGPF | Allergan files automatic shelf for debt securities, preferreds, stock
|
5/31/2012 | BKCVIG | S&P lifts health companies
|
3/13/2012 | CVIG | Fitch upgrades Allergan
|
10/31/2011 | BK | Allergan closes $800 million amended revolver, extends to 2016
|
3/16/2011 | CV | Market Commentary: RAIT Financial gains on debut; Illumina, USEC lag again; Allergan's notes trade at parity
|
3/16/2011 | CVIG | Fitch ups Allergan
|
3/14/2011 | CV | Market Commentary: USEC drops dollar neutral on Japan's nuclear crisis; Chesapeake up; Illumina, RAIT on tap
|
3/11/2011 | CV | Market Commentary: Convertibles market eyes new paper; week sees more than $2 billion of issuance; Cemex off
|
3/8/2011 | CV | Market Commentary: Allergan off on call news; Hutchinson drops; TiVo on tap; Cemex launches $1.2 billion deal
|
3/7/2011 | CVLM | Allergan calls $649.73 million 1.5% convertible senior notes due 2026
|
2/17/2011 | CV | Market Commentary: NetApp falls outright, flat on hedge; Allergan comes in slightly; KV Pharma extends gains
|
1/13/2011 | CV | Market Commentary: Dendreon to price $500 million convertibles; Allergan active amid possible short covering
|
11/1/2010 | CV | Market Commentary: Planned Stanley Black & Decker seen 3-4 points cheap; Developers Diversified up in gray
|
10/18/2010 | CV | Market Commentary: NII Holdings flat to lower on scuttled wireless agreement; EMC mixed; Cubist deal on tap
|
10/11/2010 | CV | Market Commentary: LDK adds as shares surge on raised view; Allergan steady; newish SL Green trades over par
|
9/7/2010 | CVIG | Fitch rates Allergan notes A-
|
9/7/2010 | IG | New Issue: Allergan sells $650 million 3.375% 10-year senior notes to yield Treasuries plus 80 bps
|
9/7/2010 | IG | Market Commentary: Dell, Home Depot among issuers as primary bursts with deals amid low rates; bonds trade well
|
9/7/2010 | CVIG | S&P rates Allergan notes A+
|
9/7/2010 | CVIG | Moody's rates Allergan notes A3
|
9/3/2010 | CV | Market Commentary: Convertibles quiet, ride stronger equity markets; SanDisk holds on to gains; Agco improves
|
9/1/2010 | CVIG | Moody's: Allergan unchanged
|
8/20/2010 | CV | Market Commentary: New SanDisk slips below par on debut; older SanDisk weakens; Intel active; volumes light
|
7/21/2010 | CVIG | S&P rates Allergan notes A+
|
4/27/2010 | CVIG | S&P lifts Allergan
|
3/30/2010 | CVIG | Fitch affirms Allergan
|
3/24/2010 | CV | Market Commentary: Cemex talk revised, deal upsized; new Kaiser higher, mostly quiet; MF Global up; Newmont off
|
3/5/2010 | CV | Market Commentary: Priceline trades to 101 on debut; Nektar extends gains; SandDisk retraces gains; AMD rises
|
8/21/2009 | CV | Market Commentary: Freeport higher on upbeat outlook; Mylan, Hologic, Allergan mixed; Alcoa, Newell unchanged
|
7/20/2009 | CV | Market Commentary: Human Genome surges on lupus trial; Lincare trades before earnings; CIT busy; Intel to price
|
4/23/2009 | SS | Market Commentary: Centennial buyout could let AT&T walk; Emulex auction expected; major pharma mergers predicted
|
3/31/2009 | CVIG | Fitch affirms Allergan
|
3/12/2009 | CV | Market Commentary: CV Therapeutics higher, Gilead slips on merger news; Johnson Controls convertibles move upward
|
3/5/2009 | CV | Market Commentary: Ford adds points on debt swap; financials weaker again, US Bancorp trades; BRE Properties lower
|
3/2/2009 | CVIG | Allergan files automatic shelf registration
|
12/18/2008 | CV | Market Commentary: Convertibles stronger: Mylan adds 0.5 point; strong bid on IG names; Allergan 1.5% notes up to par
|
8/1/2008 | CV | Market Commentary: Washington Mutual, Ambac Financial edge higher; General Growth strengthens; General Motors down
|
3/17/2008 | CVIG | Fitch affirms Allergan
|
2/8/2008 | CV | Market Commentary: Qimonda slips on opening day; Chiquita moves higher; Peabody ends week higher; Allergan falls on Botox warning
|
7/19/2007 | CV | Market Commentary: Newmont, CVRD see gold rush; Allergan up but no one knows why; SunPower launches early
|
5/7/2007 | CV | Market Commentary: Armor climbs on BAE buyout; Yahoo! fades with merger hopes; Gold Reserve, Chemed launch deals
|
3/22/2007 | CV | Fitch affirms Allergan
|
12/29/2006 | SP | New Issue: ABN Amro sells $0.25 million 9.5% Knock-in Reverse Exchangeables linked to Allergan
|
12/4/2006 | SP | ABN Amro to issue 9.5% Knock-In Reverse Exchangeables linked to Allergan
|
11/1/2006 | BT | Allergan product sales up 30% for the quarter, boosted by Inamed acquisition
|
9/26/2006 | BT | Allergan to launch wrinkle filler Juvederm through experience trial
|
9/19/2006 | BT | ExonHit extends research deal with Allergan to 2009, adds neurodegenerative diseases
|
8/2/2006 | BT | Allergan posts $74.2 million second quarter GAAP net income, preparing to launch Juvederm, Ganfort
|
6/23/2006 | BT | FDA approves Allergan's once-daily eye drop as first-line treatment of elevated intraocular pressure
|
6/12/2006 | CV | Market Commentary: Symantec reoffers, prices deal at cheap end of talk; NPS unmoved by restructuring; Comverse slides
|
6/12/2006 | BT | Market Commentary: NPS Pharma drops 19% to new low; Avigen up; CV Therapeutics drops 5%; Pozen pushed up 11%
|
6/5/2006 | BT | Allergan given FDA approval of Juvederm for facial wrinkles
|
6/5/2006 | BT | Allergan wins rehearing of patent suit against Apotex
|
5/25/2006 | BT | Allergan receives European approval to market Ganfort for treatment of glaucoma
|
5/5/2006 | BT | Market Commentary: Northstar Neuroscience stock climbs on upsized IPO; Praecis stock jumps 22.3% on earnings
|
5/5/2006 | CV | Market Commentary: Safenet gains on earnings, stock buyback; Scottish Re widens after poor quarter; Finisar flat after rally
|
5/3/2006 | BT | Allergan announces net sales of $615.2 million for first quarter
|
4/12/2006 | BTCV | Allergan to redeem zero-coupon convertibles due 2022
|
4/10/2006 | CV | Market Commentary: Red Hat gains 8 points outright on acquisition; Oscient keeps sliding; Rentech deal sees poor interest
|
4/7/2006 | CV | Market Commentary: Safenet convertibles gain against stock crash; Allergan falls on debut; Rentech sets talk on new deal
|
4/7/2006 | BTCV | New Issue: Allergan prices $700 million of 20-year convertibles at 1.5%, up 20%, greenshoe exercised
|
4/6/2006 | BT | New Issue: Allergan sells $800 million 10-year senior notes to yield 5.788%
|
4/6/2006 | BT | Market Commentary: Amgen a drag on biotech sector; Medarex follow-on seen on deck; Oscient up on PIPE after-hours
|
4/6/2006 | CV | Allergan prices $700 million convertibles to yield 1.5%, up 20%
|
4/6/2006 | CV | Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
|
4/5/2006 | BTCV | Allergan to redeem zero-coupon convertibles due 2022
|
4/5/2006 | BT | Allergan to sell $800 million 10-year notes
|
4/5/2006 | BT | Market Commentary: Allergan rolls out $700 million note; Discovery falls on FDA request for more data; Human Genome up
|
4/5/2006 | CV | Market Commentary: Conexant gains on report; ON Semiconductor up despite downgrade; Ciena struggles off the blocks
|
4/5/2006 | BTCV | Allergan to offer $700 million of 20-year convertibles talked at 1%-1.5%, up 20% to 25%
|
4/4/2006 | BT | Allergan gets $800 million amended and restated revolver
|
4/4/2006 | BTCV | Moody's rates Allergan notes, convertibles A3
|
3/29/2006 | BTCV | Fitch downgrades Allergan
|
3/28/2006 | BTCV | S&P affirms Allergan
|
3/27/2006 | BT | Allergan predicts 21% to 27% jump in sales during 2006
|
3/9/2006 | BT | Allergan, Alcon reach agreement on brimonidine 0.15% patent litigation
|
3/6/2006 | BT | Acadia, Allergan extend research agreement to 2008
|
12/13/2005 | BT | Inamed board recommends shareholders accept Allergan's $3.2 billion merger offer
|
12/13/2005 | BT | Medicis, Inamed terminate merger deal; Inamed pays $90 million fee, clearing way for Allergan offer
|
12/13/2005 | BT | Market Commentary: CuraGen sinks; Indevus soars; Voyager pulls IPO; Insmed up on FDA approval; Tercica falls
|
12/6/2005 | BT | Inamed's board says Allergan's $3.2 billion merger offer tops Medicis offer, but remains neutral
|
11/22/2005 | BT | Medicis wants Inamed to recommend that stockholders reject Allergan's rival merger offer
|
11/21/2005 | BT | Market Commentary: Incyte zooms on R&D pact with Pfizer; Medicis, Mentor, Allergan, Inamed tangle in merger scuffle
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
11/15/2005 | BTCV | Moody's may cut Allergan long-term ratings
|
11/15/2005 | BTCV | S&P places Allergan on negative watch
|
11/15/2005 | BTCV | Fitch places Allergan on negative watch
|
11/15/2005 | CV | Market Commentary: Ford, GM, oil and gas, airlines down; EDO shows up in the gray; Pantry, C&D, E*Trade deals ahead
|
11/15/2005 | BT | Allergan unveils $3.2 billion bid for Inamed, topping Medicis offer by $450 million
|
11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
10/24/2005 | BT | NPS teams with Allergan to promote Restasis to rheumatologists
|
6/30/2005 | BT | Allergan initiated by Leerink Swann at market perform
|
4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
2/9/2005 | CV | Market Commentary: Protein Design Labs sweetened, sinks; Huntsman hotly pursued; Allergan, Sepracor off, Saks up
|
7/13/2004 | CV | S&P: Allergan unaffected
|
10/15/2003 | CV | S&P ups Teva to BBB
|
7/22/2003 | CV | Market Commentary: Buyers tiptoeing back into market as premiums contract; Wells Fargo rekindles dividend fears
|
7/11/2003 | CV | Lehman finds options market signaling several converts have high dividend risk
|
5/7/2003 | CV | Allergan plans to redeem remaining convertibles due 2020 in November
|
4/28/2003 | CV | S&P ups AmeriSource-Bergen
|
12/17/2002 | CV | Allergan says $588 million principal LYONs tendered
|
11/18/2002 | CV | Market Commentary: Trickle of new issues providing hope for eager buyers
|
11/18/2002 | CV | Allergan starts tender offer of 0% LYONs due 2020
|
11/7/2002 | CV | Market Commentary: Faithful players trudge on with buying strategy amidst retreat
|
11/5/2002 | CV | Market Commentary: New deals improve trading flow as market awaits Fed
|
11/1/2002 | CV | Moody's cuts Nortel
|
11/1/2002 | CV | Market Commentary: Allergan new 0% convertible takes center stage and trades higher on quiet Friday
|
10/31/2002 | CV | New Issue: Allergan $450 million proceeds convertible yields 1.25%, up 25.45%
|
10/31/2002 | CV | Market Commentary: Firm tone on rising confidence; Allergan prices $450 million, Lucent, EDS active
|
10/24/2002 | CV | S&P keeps AOL Time Warner on watch
|
9/23/2002 | CV | Fitch lowers Teco Energy
|
6/21/2002 | CV | Deutsche: Allergan seen at discount due to uncertainty with Advanced Medical spin-off
|
4/12/2002 | CV | Market Commentary: Quiet session ends quiet week on higher note; Cendant lower on accounting questions
|
1/22/2002 | CV | Moody's downgrades Kmart
|